Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIXC NASDAQ:BCAB NASDAQ:NEUP NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.37-0.4%$1.29$0.92▼$8.81$27.86M0.5263,325 shs17,143 shsBCABBioAtla$5.01+15.2%$6.87$3.92▼$71.50$8.32M0.8146,867 shs37,528 shsNEUPNeuphoria Therapeutics$5.20-2.6%$4.64$3.64▼$21.40$28.03M0.7245,306 shs11,847 shsRNTXRein Therapeutics$1.18+0.9%$1.38$1.00▼$2.40$33.09M1.42359,299 shs141,707 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics-4.17%-5.48%+11.29%-2.82%+137,999,900.00%BCABBioAtla-3.33%+3.33%-6.65%-58.69%-80.54%NEUPNeuphoria Therapeutics-0.74%+1.33%+16.09%+33.17%+8.32%RNTXRein Therapeutics0.00%-13.65%-25.95%+2.63%-28.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.37-0.4%$1.29$0.92▼$8.81$27.86M0.5263,325 shs17,143 shsBCABBioAtla$5.01+15.2%$6.87$3.92▼$71.50$8.32M0.8146,867 shs37,528 shsNEUPNeuphoria Therapeutics$5.20-2.6%$4.64$3.64▼$21.40$28.03M0.7245,306 shs11,847 shsRNTXRein Therapeutics$1.18+0.9%$1.38$1.00▼$2.40$33.09M1.42359,299 shs141,707 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics-4.17%-5.48%+11.29%-2.82%+137,999,900.00%BCABBioAtla-3.33%+3.33%-6.65%-58.69%-80.54%NEUPNeuphoria Therapeutics-0.74%+1.33%+16.09%+33.17%+8.32%RNTXRein Therapeutics0.00%-13.65%-25.95%+2.63%-28.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIXCQualigen Therapeutics 1.00SellN/AN/ABCABBioAtla 2.00Hold$200.003,892.02% UpsideNEUPNeuphoria Therapeutics 2.25Hold$21.00303.85% UpsideRNTXRein Therapeutics 2.00Hold$8.00577.97% UpsideCurrent Analyst Ratings BreakdownLatest BCAB, AIXC, RNTX, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026AIXCQualigen Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIXCQualigen TherapeuticsN/AN/AN/AN/A($0.75) per shareN/ABCABBioAtla$2M4.16N/AN/A($28.51) per share-0.18NEUPNeuphoria Therapeutics$15.65M1.79$0.15 per share34.52$10.11 per share0.51RNTXRein TherapeuticsN/AN/A$0.06 per share20.46($1.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIXCQualigen Therapeutics-$16.97M-$7.50N/AN/AN/AN/AN/A-83.21%N/ABCABBioAtla-$59.61M-$50.50N/AN/AN/AN/AN/A-257.22%5/12/2026 (Estimated)NEUPNeuphoria Therapeutics-$370K-$4.42N/AN/AN/AN/A-25.98%-18.39%5/19/2026 (Estimated)RNTXRein Therapeutics-$49.87M-$1.96N/AN/AN/AN/A-510.35%-56.38%N/ALatest BCAB, AIXC, RNTX, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026N/ANEUPNeuphoria Therapeutics-$0.56N/AN/AN/AN/AN/A5/12/2026Q1 2026BCABBioAtla-$10.00N/AN/AN/A$1.72 millionN/A3/31/2026Q4 2025BCABBioAtla-$18.00-$8.00+$10.00-$8.00$0.70 million$2.00 million3/30/2026Q4 2025AIXCQualigen TherapeuticsN/A-$3.76N/A-$3.76N/AN/A2/17/2026Q2 2026NEUPNeuphoria Therapeutics-$0.56-$0.77-$0.21-$0.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIXCQualigen TherapeuticsN/AN/AN/AN/AN/ABCABBioAtlaN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIXCQualigen TherapeuticsN/A9.309.30BCABBioAtlaN/A0.370.37NEUPNeuphoria TherapeuticsN/A9.049.04RNTXRein TherapeuticsN/A0.700.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIXCQualigen Therapeutics3.18%BCABBioAtla77.23%NEUPNeuphoria Therapeutics15.90%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipAIXCQualigen Therapeutics1.17%BCABBioAtla11.77%NEUPNeuphoria Therapeutics1.50%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIXCQualigen Therapeutics5020.24 million20.00 millionN/ABCABBioAtla601.66 million1.46 millionOptionableNEUPNeuphoria TherapeuticsN/A5.39 million5.31 millionN/ARNTXRein Therapeutics928.04 million26.61 millionN/ABCAB, AIXC, RNTX, and NEUP HeadlinesRecent News About These CompaniesRein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common StockApril 30, 2026 | globenewswire.comRein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary FibrosisApril 29, 2026 | globenewswire.comRein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in AprilApril 26, 2026 | marketbeat.comRein Therapeutics Stock Short Interest Report | NASDAQ:RNTX | BenzingaApril 14, 2026 | benzinga.comRein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary FibrosisMarch 3, 2026 | markets.businessinsider.comRein Therapeutics (RNTX) price target increased by 25.00% to 10.20February 4, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Rein Therapeutics (RNTX), Zimmer Biomet Holdings (ZBH) and Theravance Biopharma (TBPH)January 23, 2026 | theglobeandmail.comRein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary FibrosisJanuary 20, 2026 | manilatimes.netMRein Therapeutics (NASDAQ:RNTX) Shares Down 0.8% – Here’s WhyJanuary 9, 2026 | defenseworld.netDVoss Capital, Lp Buys 104,183 Shares of Rein Therapeutics (NASDAQ:RNTX) StockNovember 19, 2025 | insidertrades.comRein Therapeutics (RNTX) Price Target Decreased by 20.00% to 8.16November 17, 2025 | msn.comRein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPFNovember 6, 2025 | finance.yahoo.comRein Therapeutics upgraded to Buy from Hold at BrooklineNovember 4, 2025 | msn.comWhy Is Rein Therapeutics Stock Trading Higher On Monday?November 3, 2025 | benzinga.comRein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisNovember 3, 2025 | taiwannews.com.twTRein Therapeutics Inc. Stock (RNTX) Opinions on Institutional Investments and Funding DealsOctober 29, 2025 | quiverquant.comQInsider Buying: Rein Therapeutics (NASDAQ:RNTX) Major Shareholder Purchases 30,176 Shares of StockOctober 29, 2025 | insidertrades.comRein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisOctober 9, 2025 | globenewswire.comRein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20October 1, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Rein Therapeutics (RNTX) with Buy RecommendationSeptember 22, 2025 | msn.comRein Therapeutics initiated with a Buy at H.C. WainwrightSeptember 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAB, AIXC, RNTX, and NEUP Company DescriptionsQualigen Therapeutics NASDAQ:AIXC$1.37 -0.01 (-0.43%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.BioAtla NASDAQ:BCAB$5.01 +0.66 (+15.17%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Neuphoria Therapeutics NASDAQ:NEUP$5.20 -0.14 (-2.62%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Rein Therapeutics NASDAQ:RNTX$1.18 +0.01 (+0.85%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
